The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous X None **Names**

Entity Type

Other (Specify)

0001420565

DELAWARE

Name of Issuer

X Corporation

Limited Partnership AILERON THERAPEUTICS INC Limited Liability Company

Jurisdiction of General Partnership **Incorporation/Organization Business Trust**

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

AILERON THERAPEUTICS INC

Street Address 2 Street Address 1

281 ALBANY STREET

State/Province/Country ZIP/PostalCode **Phone Number of Issuer** City

CAMBRIDGE MASSACHUSETTS 02139 617-995-0900

3. Related Persons

Last Name First Name Middle Name

Yanchik III Joseph A.

> **Street Address 1 Street Address 2**

281 Albany Street

State/Province/Country ZIP/PostalCode City

Cambridge **MASSACHUSETTS** 02139

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Ambros Reinhard J.

> **Street Address 1 Street Address 2**

281 Albany Street

City State/Province/Country ZIP/PostalCode

Cambridge **MASSACHUSETTS** 02139

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name Gallagher, Jr. Brian M. **Street Address 1 Street Address 2** 281 Albany Street **State/Province/Country** ZIP/PostalCode City Cambridge **MASSACHUSETTS** 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name Harrison Seth L. **Street Address 1 Street Address 2** 281 Albany Street City State/Province/Country ZIP/PostalCode Cambridge **MASSACHUSETTS** 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name Middle Name** Kapnick Scott **Street Address 1** Street Address 2 281 Albany Street **State/Province/Country** ZIP/PostalCode City **MASSACHUSETTS** Cambridge 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name Middle Name** McArthur John H. **Street Address 1 Street Address 2** 281 Albany Street State/Province/Country ZIP/PostalCode City Cambridge **MASSACHUSETTS** 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name Winder Caleb **Street Address 1 Street Address 2** 281 Albany Street ZIP/PostalCode City **State/Province/Country MASSACHUSETTS** Cambridge 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name Shanafelt Armen **Street Address 1** Street Address 2 281 Albany Street ZIP/PostalCode State/Province/Country City Cambridge **MASSACHUSETTS** 02139

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Aivado Manuel

Street Address 1 Street Address 2

281 Albany Street

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing
Banking & Financial Services X Biotechnology Restaurants
Commercial Banking Health Insurance Technology

Investing

Health Insurance

Hospitals & Physicians

Computers

Investment Banking Pharmaceuticals Telecommunications
Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel an investment company under Real Estate Airlines & Airports

the Investment Company
Act of 1940?

Commercial

Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Real Estate

Other Banking & Financial Services REITS & Finance Other Travel
Business Services Residential

Business Services Residential Other
Energy

Coal Mining

5. Issuer Size

Oil & Gas

Other Energy

Electric Utilities

Energy Conservation
Environmental Services

Revenue Range OR Aggregate Net Asset Value Range

No Revenues No Aggregate Net Asset Value

\$1 - \$1,000,000 \$1 - \$5,000,000

\$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$5,000,001 - \$25,000,000 \$25,000,000

\$25,000,001 -\$100,000,000 \$50,000,001 - \$100,000,000

Over \$100,000,000

X Decline to Disclose
Not Applicable

Over \$100,000,000

Decline to Disclose
Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Investment Company Act Section 3(c)

Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 505 X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5)	Section 3(c) Section 3(c) Section 3(c) Section 3(c) Section 3(c)	c)(2) c)(3) c)(4) c)(5) c)(6)	Section 3(c)(9) Section 3(c)(10) Section 3(c)(11) Section 3(c)(12) Section 3(c)(13) Section 3(c)(14)		
X New Notice Date of First Sale 2016-12-23	First Sala Vot t	o Occur			
Amendment	riist sale Tet t	.o Occui			
8. Duration of Offering					
Does the Issuer intend this offering to last more th	an one year?	Yes X No			
9. Type(s) of Securities Offered (select all that app	ly)				
X Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other Right to Acquire Security Other (describe) Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)					
10. Business Combination Transaction					
Is this offering being made in connection with a beau a merger, acquisition or exchange offer?	ısiness combii	nation transac	tion, such as Yes X No		
Clarification of Response (if Necessary):					
11. Minimum Investment					
Minimum investment accepted from any outside is	nvestor \$0 US	SD			
12. Sales Compensation					
Recipient	R	Recipient CRD	Number X None		
(Associated) Broker or Dealer X None		Associated) B Number	roker or Dealer CRD	X None	
Street Address 1			Street Address 2		
City	St	tate/Province/	Country		ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All Statesâ€∏ or check individual States	All States	Foreign/non-	US		
13. Offering and Sales Amounts					
Total Offering Amount \$40,000,000 USD or	Indefinite				
Total Amount Sold \$30,112,894 USD					
Total Remaining to be Sold \$9,887,106 USD or	Indefinite				

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited

Clarification of Response (if Necessary):

14. Investors

investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
AILERON THERAPEUTICS	/s/ Joseph A. Yanchik	Joseph A. Yanchik	President and Chief Executive	2017-01-
INC	III	III -	Officer	06

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this

dertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's eservation of their anti-fraud authority.					